Rushipat

1
Antipsychotic Drugs Market Size Worlds Top 10
Industry Share CAGR of 4.0 Forecast 2019 to
2026 Key Companies Covered in the Antipsychotic
Drugs Market Research Report Are H. Lundbeck
A/S, Otsuka Pharmaceutical Co., Ltd., Janssen
Pharmaceuticals, Inc., Eli Lilly and Company,
AstraZeneca, ALLERGAN, Vanda Pharmaceuticals
Inc., Sumitomo Dainippon Pharma Co., Ltd.,
Alkermes plc, Pfizer Inc., Bristol-Myers Squibb
Company and, Other Prominent Players The
schizophrenia segment emerged dominant in the
global antipsychotic drugs market in 2018. The
segment had acquired an astonishing 45.2 of the
global antipsychotic drugs market share in the
same year owing to the rising prevalence of the
disorder. This information is published in a
report by Fortune Business Insights, titled,
Antipsychotic Drugs Global Market Analysis,
Insights and Forecast, 2019-2026. According to
the report, the global market was worth US
14,963.5 Mn in 2018. However, Fortune Business
Insights predicts that the global market will
reach US 20,539.5 Mn by 2026, exhibiting a CAGR
of 4.0 in the forecast period. Browse Complete
Report https//www.fortunebusinessinsights.com/in
dustry-reports/antipsychotic-drugs-market-101390 M
ajor Leading Players Mentioned

H. Lundbeck A/S Otsuka Pharmaceutical Co., Ltd.
Janssen Pharmaceuticals, Inc. Eli Lilly and
Company AstraZeneca ALLERGAN Vanda
Pharmaceuticals Inc. Sumitomo Dainippon Pharma
Co., Ltd. Alkermes plc Pfizer Inc. Bristol-Myers
Squibb Company Other Prominent Players
The report on antipsychotic drugs market provides
insights into growth opportunities for investors
and businesses alike and growth drivers and
trends in the market. It offers quantitative and
qualitative information on the drivers and growth
rate of the segments in the market. The report
also comprises of extensive primary and secondary
research which aid in providing clients with a
clear picture of the anticipated market size and
current market scenario. Rapid Shift Towards
Advanced and Safe Drugs to Favor Growth in North
America
2
Geographically, the global antipsychotic drugs
market is grouped into Latin America, Asia
Pacific, North America, the Middle East and
Africa, and Europe. Amongst these regions, North
America had acquired US 9,307.3 Mn antipsychotic
drugs market revenue in the year 2018. The
growth is attributed to the increasing patient
pool suffering from psychotic disorders in the
region. Additionally, a rapid shift of these
patients towards safe antipsychotic drugs for
the treatment of schizophrenia, bipolar disorder,
and other psychotic diseases is expected to
drive the antipsychotic drugs market in this
region. Several healthcare organizations in North
America have also begun promoting such drugs for
treatment.

• Global Antipsychotic Drugs Market Segmentation
• By Disease
• Schizophrenia
• Bipolar Disorder
• Unipolar Depression
• Dementia
• Others
• By Therapeutic Class
• First Generation
• Second Generation
• Third Generation
• By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

In Asia Pacific, emerging countries, such as
India, China, and other Southeast Asian countries
have a large patient pool who are suffering from
various disorders, especially schizophrenia.
Moreover, the populace residing in these
countries are preferring second-generation drugs
over first-generation antipsychotic drugs. It is
because of the increasing healthcare expenditure
and increasing awareness programs regarding the
usage of these drugs. Fortune Business Insights
predicts that Europe would follow the footsteps
of North America and would remain in the second
position throughout the forecast period. The
growth is attributed to a rise in the patient
population and increasing incidence of psychotic
diseases. Get Sample PDF https//www.fortunebusin
essinsights.com/enquiry/request-sample-pdf/antipsy
chotic-drugs-market- 101390 Indivior, Otsuka,
Allergan and Other Market Players Receive Fast
Track Approvals
3

• Fortune Business Insights has listed a few key
  developments that have occurred in the global
  antipsychotic drugs market since the past few
  years
• Indivior PLC, a specialty pharmaceuticals
  business based in the U.K., declared in July
  2018 that it received FDA approval for Perseris,
  a long-acting injectable (LAI) containing
  risperidone. It is used to treat schizophrenia in
  adults. Perseris uses the extended-release
  delivery system that provides a certain level of
  risperidone which sustains over a month.
  According to the company, the FDA approval will
  support adult patients and their healthcare
  providers by providing a technologically advanced
  treatment option.
• Otsuka Pharmaceutical Co., Ltd., a pharmaceutical
  company, headquartered in Tokyo, announced the
  launch of Rexulti in Japan in April 2018. Rexulti
  is available in both 1mg and 2mg variants for
  the treatment of schizophrenia. It is already
  available in the pharmacies in Australia,
  Canada, and the U.S. The efficacy and safety of
  Rexulti were examined in four clinical phase III
  studies that were controlled by placebo. The
  tablets were superior for the treatment of
  schizophrenia when provided at specific dosages.
  Otsuka recommends giving the patients a lower
  dose during the initial treatment procedure and
  then slowly increase the dosage over time. They
  are to be consumed regularly with or without
  meals.
• Allergan, a pharmaceutical company based in
  Ireland, declared that the FDA approved Vraylar
  in May 2019. As per the approval, Vraylar can now
  be used in the treatment of depressive episodes
  that are associated with bipolar depression
  (bipolar I disorder) in adult patients. In the
  U.S., Vraylar can also be used to treat manic
  episodes occurring due to bipolar I disorder.
• Speak to Analyst
• https//www.fortunebusinessinsights.com/enquiry/sp
  eak-to-analyst/antipsychotic-drugs-market-
  101390
• View More Reports
• Rheumatoid Arthritis Therapeutics Market Size
  Worlds Top 10 Industry Share CAGR of 4.6
  Forecast 2018 to 2025
• Gene Therapy Market Size, Forecast, Overview,
  Analysis Pfizer, Novartis, Bayer Sanofi,
  GSK,Amgen
• Cannabis Marijuana Market Size to Exhibit 32.6
  CAGR Forecast till 2026 Legalization of
  Medical Marijuana in Most Countries to Propel
  Striking Growth

About Us
4
Fortune Business Insights offers expert corporate
analysis and accurate data, helping
organizations of all sizes make timely decisions.
We tailor innovative solutions for our clients,
assisting them to address challenges distinct to
their businesses. Our goal is to empower our
clients with holistic market intelligence, giving
a granular overview of the market they are
operating in. Our reports contain a unique mix of
tangible insights and qualitative analysis to
help companies achieve sustainable growth. Our
team of experienced analysts and consultants use
industry-leading research tools and techniques to
compile comprehensive market studies,
interspersed with relevant data. At Fortune
Business Insights, we aim at highlighting the
most lucrative growth opportunities for our
clients. We, therefore, offer recommendations,
making it easier for them to navigate through
technological and market-related changes. Our
consulting services are designed to help
organizations identify hidden opportunities and
understand prevailing competitive
challenges. Contact Us Authors Bio Name
Reeti Banerjee Reeti Banerjee is currently
working as a content writer in a prominent market
research firm named Fortune Business Insights.
She specializes in writing articles, press
releases, blogs, and news reports. She believes
in maintaining simplicity throughout her content
to provide the clients with a seamless reading
experience. LinkedIn Profile www.linkedin.com/in/
reeti-banerjee-45462811b/